In the competitive field of Cancer Drugs, companies are constantly innovating to stay ahead. Discover the latest patent opposition trends, top opposing and opposed companies, and the most recent patents getting opposed. Stay informed on the latest developments in Cancer Drugs technology and learn how to protect your intellectual property.

Get Comprehensive Patent Opposition Report for the Cancer Drugs Industry

Gain strategic insights, uncover critical details, and make informed decisions with expert-backed analysis.

Get Your Report Now

Explore the top companies that have filed the most patent oppositions in the technology industry.

Explore the top companies that have faced the most patent oppositions in the technology industry.

Patent challenges are becoming increasingly common in the Cancer Drugs industry as companies work to protect their innovations in a highly competitive market. These legal battles can significantly impact the development and release of new technologies. Below is a list of the latest patents that have been opposed in the Cancer Drugs industry, offering a snapshot of the ongoing struggles over intellectual property rights. For anyone involved in this industry, understanding these patent disputes is essential for navigating its future.

Last updated on: Jul 24, 2025
Patent NumberTitleApplicantOpposition DateOpposition Name

Get alerts on new patent oppositions in the Cancer Drugs industry

EP3882275Anti-Pd-1 And Anti-Vegfa Bifunctional Antibody, Pharmaceutical Composition Thereof And Use ThereofAKESO BIOPHARMAJun 18, 2025STRAWMAN
EP4241849Uses For And Article Of Manufacture Including Her2 Dimerization Inhibitor PertuzumabF HOFFMANN LA ROCHEJun 18, 2025STORZ
EP4241849Uses For And Article Of Manufacture Including Her2 Dimerization Inhibitor PertuzumabF HOFFMANN LA ROCHEJun 17, 2025LANYON OPPOSITIONS
EP4069254Combination Decitabine And Cedazuridine Solid Oral Dosage FormsOTSUKA PHARMACEUTICALJun 11, 2025BOTTI & FERRARI
EP4084779Compositions Of 1-(4-Bromo-5-(1-Ethyl-7-(Methylamino)-2-Oxo-1,2-Dihydro-1,6-Naphthyridin-3-Yl)-2-Fluorophenyl)-3-PhenylureaDECIPHERA PHARMACEUTICALSMay 28, 2025ALFRED E TIEFENBACHER
EP3638243Methods For Treating Myeloproliferative Neoplasm-Associated Myelofibrosis And AnemiaCELGENEMay 7, 2025MAIWALD
EP3638243Methods For Treating Myeloproliferative Neoplasm-Associated Myelofibrosis And AnemiaCELGENEMay 5, 2025WUESTHOFF & WUESTHOFF PATENTANWALTE PARTG MBB
EP4241767Novel Lipids And Compositions For The Delivery Of TherapeuticsARBUTUS BIOPHARMAApr 29, 2025MODERNATX
EP3439662Liquid Formulations Of (S)-N-(5-((R)-2-(2,5-Difluorophenyl)-Pyrrolidin-1-Yl)-Pyrazolo[1,5-A]Pyrimidin-3-Yl)-3-Hydroxypyrrolidine-1-CarboxamideLOXO ONCOLOGYApr 11, 2025SYNTHON
EP3782986Heterocyclic CompoundTAKEDA PHARMACEUTICALApr 10, 2025DE CLERCQ & PARTNERS

To stay ahead in the competitive Cancer Drugs industry, companies are constantly innovating. Here are the top patents facing oppositions in the Cancer Drugs industry. Stay informed on the latest opposition trends and learn how to protect your intellectual property.

Last updated on: Jul 24, 2025
Patent NumberGrant DateTitleApplicantTotal Oppositions
EP2478907Apr 14, 2021Methods And Compositions For Treating CancerJANSSEN ONCOLOGY22
EP2962690Jan 16, 2019(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions ThereofCELGENE15
EP2493466Mar 10, 2021Novel Antitumoral Use Of CabazitaxelSANOFI MATURE13
EP3725778Aug 18, 2021Formulations Of EnzalutamideASTELLAS PHARMA11
EP3078667Nov 21, 2018Formulation Of Boronic Acid CompoundsTHE UNITED STATES OF AMERICA11
EP3342411Aug 21, 2019Rapamycin Derivative For Treating Pancreas CancerNOVARTIS10
EP3616720Feb 17, 2021Pharmaceutical Composition For Cancer TreatmentSHIONOGI10
EP3322731Jan 13, 2021Method Of Treating Cancer Using Immune Checkpoint InhibitorBRISTOL MYERS SQUIBB9
EP3351246Sep 18, 2019Rapamycin Derivative For The Treatment Of A Solid Tumor Associated With Deregulated AngiogenesisNOVARTIS9
EP2269603May 20, 2015Treatment Of Solid Tumours With Rapamycin DerivativesNOVARTIS9